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Loss of TBK1 is a frequent cause of
frontotemporal dementia in a Belgian
cohort
ABSTRACT
Objective: To assess the genetic contribution of TBK1, a gene implicated in amyotrophic lateral
sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS patient
cohorts containing a significant part of genetically unresolved patients.
Methods:We sequenced TBK1 in a hospital-based cohort of 482 unrelated patients with FTD and
FTD-ALS and 147 patients with ALS and an extended Belgian FTD-ALS family DR158. We
followed up mutation carriers by segregation studies, transcript and protein expression analysis,
and immunohistochemistry.
Results:We identified 11 patients carrying a loss-of-function (LOF) mutation resulting in an overall
mutation frequency of 1.7% (11/629), 1.1% in patients with FTD (5/460), 3.4% in patients with
ALS (5/147), and 4.5% in patients with FTD-ALS (1/22). We found 1 LOFmutation, p.Glu643del,
in 6 unrelated patients segregating with disease in family DR158. Of 2 mutation carriers, brain
and spinal cord was characterized by TDP-43-positive pathology. The LOF mutations including
the p.Glu643del mutation led to loss of transcript or protein in blood and brain.
Conclusions: TBK1 LOF mutations are the third most frequent cause of clinical FTD in the Belgian
clinically based patient cohort, after C9orf72 and GRN, and the second most common cause of
clinical ALS after C9orf72. These findings reinforce that FTD and ALS belong to the same dis-
ease continuum. Neurology® 2015;85:2116–2125
GLOSSARY
ALS5 amyotrophic lateral sclerosis; bvFTD 5 behavioral variant frontotemporal dementia; FTD5 frontotemporal dementia;
FTLD 5 frontotemporal lobar degeneration; KD 5 kinase domain; LOF 5 loss of function; NCI 5 neuronal cytoplasmic
inclusions; Ser172 5 serine 172.
Frontotemporal lobar degeneration (FTLD) is a heterogeneous neurodegenerative disorder asso-
ciated with amyotrophic lateral sclerosis (ALS) in approximately 10%–15% of patients with
frontotemporal dementia (FTD).1 Evidence that common disease pathways are involved in FTD
and ALS stems from the observation of families and individual patients in which both diseases
occur (FTD-ALS),1 and the TDP-43 inclusions in both patient groups.2
Nearly 50% of FTD cases and 10% of ALS cases aggregate in families, suggesting a strong genetic
component. The most convincing genetic evidence for a common pathomechanism is provided by
the repeat expansion mutations in C9orf72 in patients with FTD, ALS, and FTD-ALS.3–5 Recently,
TBK1 loss-of-function (LOF) mutations were identified in patients with ALS6,7 and FTLD-TDP.8
In the Belgian FTD cohort, mutations in known genes accounted for 30% of familial FTD
and 75% of familial FTD-ALS, with several families with autosomal dominant inheritance
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remaining genetically unresolved.5,9 Here, we
investigated the genetic role of TBK1 in a Bel-
gian cohort of 629 patients with FTD, FTD-
ALS, and ALS.
METHODS Subjects. Our study population consisted of 482
patients with FTD, 22 of whom had concomitant ALS (FTD-
ALS), and 147 patients with ALS ascertained in Belgium through
an ongoing multicenter collaboration of neurology departments
and memory clinics partnering in the Belgian Neurology
(BELNEU) consortium. Additional patients were included who
had initially been referred to the Diagnostic Service Facility for
medical genetic testing. Patients were diagnosed using a
standard protocol and established clinical criteria.10–12
Postmortem neuropathologic analysis confirmed diagnosis in 25
patients with FTD, 3 patients with FTD-ALS, and 6 patients
with ALS. A positive familial history, i.e., at least one first-
degree relative with a FTD-ALS spectrum disease, was recorded
in 132 patients with FTD (28.7%), 4 patients with FTD-ALS
(36.4%), and 18 patients with ALS (12.2%). Of these familial
index patients, 93 cases of FTD (70.5%), 1 case of FTD-ALS
(25.0%) and 7 cases of ALS (38.9%) were not explained by
mutations in the known FTLD and ALS genes (MAPT, GRN,
C9orf72, VCP, CHMP2B, FUS, TARDBP, SOD1), in the AD
genes (PSEN1, PSEN2, APP), or in the prion gene (PRNP). One
patient with unexplained FTD-ALS was the index patient of a
4-generation family (family DR158), of which we collected
genomic DNA and generated lymphoblast cell lines of 38
individuals including 4 patients in generation III (figure 1 and
table 1). A Belgian control cohort of 1,044 persons free of
personal and familial history of neurodegenerative or psychiatric
diseases and with a Mini-Mental State Examination score .26
was also analyzed.
Standard protocol approvals, registrations, and patient
consents. All participants provided written informed consent for
participation in clinical, pathologic, and genetic studies. Clinical
study protocols and informed consent forms were approved by
the local medical ethics committees of the collaborating clinical
centers. Genetics study protocol and informed consent forms
were approved by the medical ethics committees of the University
Hospital Antwerp and the University of Antwerp.
Experimental procedures. Nineteen coding TBK1 exons were
amplified in multiplex PCR reactions using MASTR technology
(http://www.multiplicom.com) and sequenced on a MiSeq
platform (Illumina; San Diego, CA) and 1 exon was analyzed by
Sanger sequencing. Identified variants were validated and relatives of
mutation carriers were analyzed using Sanger sequencing.
TBK1 transcripts were measured in lymphoblast cells of 8 muta-
tion carriers and frontal cortex of 2 carriers using real-time PCR
amplification of a TBK1amplicon, quantified against 2 housekeep-
ing genes. We sequenced real-time PCR products to establish the
transcribed alleles based on the coding mutation or the coding pol-
ymorphism rs7486100. We used western blotting of protein lysates
of lymphoblast cells and brain with a monoclonal antibody against
TBK1 and quantified against GAPDH. We performed neuropath-
ologic analysis of brain and spinal cord of 2 TBK1mutation carriers.
Appendix e-1 on the Neurology® Web site at Neurology.org
contains further technical details.
RESULTS TBK1 mutation analysis and the effect on
transcript and protein expression.We screened the cod-
ing region of TBK1 and identified 2 frameshift,
1 nonsense, 1 splice site mutation, and 2 single amino
acid deletions in 11 unrelated index patients (table 1,
table e-1, and figure e-1). Further, we identified 5
missense mutations in 5 patients. Copy number var-
iation analysis of all TBK1 exons did not reveal exonic
or whole gene deletions or duplications.
We predicted that the nonsense and frameshift mu-
tations resulted in a premature termination codon lead-
ing to mRNA degradation by nonsense-mediated
decay. cDNA sequencing of TBK1 in lymphoblast cells
of the Ser398Profs*11 carrier, and in brain of the p.
Ser518Leufs*32 carrier, did not identify the mutant
allele, suggesting a complete loss of the mutant tran-
script. Quantification of TBK1 transcripts demon-
strated a highly reduced gene expression that was
restored to normal levels using an inhibitor of protein
synthesis (figure 2). Western blot analysis demon-
strated near 50% reduction of protein expression in
lymphoblast cells and in brain (figure 3).
In DR189, a mutation affecting the intron 8 splice
donor site resulted in in-frame skipping of exon 8 in
lymphoblast cells and brain. In addition, use of a
cryptic splice site in exon 8 resulted in an out-of-
frame transcript (figure 2). Quantitative PCR analysis
showed 30% reduced expression in lymphoblast cells
and 50% reduced expression in brain (figure 2).
Western blot analysis detected only the normal-
sized protein band with 45% reduced expression in
lymphoblast cells and 34% in brain lysates, suggest-
ing that no stable protein was produced from the
mutant transcripts (figure 3).
In lymphoblast cells of patients carrying the in-frame
deletion mutations, p.Asp167del and p.Glu643del
(n 5 5), TBK1 transcript expression was not reduced.
Also, cDNA sequencing showed the presence of both
alleles. However, we observed a significantly reduced
protein level of 44% in the p.Glu643del carriers (p 5
0.0017). In the p.Asp167del carrier, protein expression
was not altered (figure 3).
The 5 missense mutations were scattered over the 4
functional domains (table e-1 and figure e-1). Three
missense mutations—p.Arg271Leu, p.His322Tyr, and
p.Ile515Thr—were absent from 1,044 control individ-
uals. We observed p.Ala535Thr in 1 male control (age
at inclusion 63 years), and p.Lys291Glu in a male con-
trol and a female control (age at inclusion 67 and 69
years). Two mutations, p.Arg271Leu and p.Ala535Thr,
were predicted neutral, while the other 3 mutations
received variable effects using 3 prediction algorithms.
Missense mutation carriers did not show reduced tran-
script and protein expression levels (figure e-2).
DR158 family, segregation, and sharing of p.Glu643del.
Six unrelated index patients carried the p.Glu643del
mutation (table 1), among them index patient III-8
of autosomal dominant FTD-ALS family DR158,
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containing 13 patients (table 1 and figure 1). Ten
patients of family DR158 were diagnosed with a
dementia syndrome, i.e., FTD (n 5 4) or
unspecified dementia (n 5 6), while 2 patients had
a diagnosis of ALS. The mean onset age was 69.1 6
7.7 years, with a mean disease duration of 6.4 6 3.9
years. The 5 patients with FTD or FTD-ALS
presented with bvFTD (table e-2). Remarkably,
memory loss and disorientation were present relatively
early in the disease in most of the p.Glu643del
mutation carriers (table e-2). However, most of
these patients also developed early behavioral
problems. One patient with ALS (III-1) and
1 patient with FTD-ALS (III-8) presented with
ALS with spinal onset (table e-2), both showing
signs of motor neuron disease on EMG. Analysis of
Figure 1 Pedigrees show segregation and disease haplotype sharing in patients and families with the TBK1 mutation p.Glu643del
To protect the privacy of the participants, wemasked the sex of each person, scrambled the pedigree of family DR158, and did not specify the number of at-
risk individuals tested shown in the white diamonds. The index patient is indicated with an arrow. Filled symbols represent patients, with their age at onset
(AAO) in years below their symbol. Age at death (AAD) is shown for individuals who died in old age without symptoms. In family DR663, 3 of the 4 children
also carry a repeat expansion mutation in C9orf72, 2 affected (I-1 and II-2) and 1 asymptomatic (II-4), for whom the age at last examination (AALE) is given.
An asterisk identifies the family members for whom genomic DNA was available. The Glu643del mutation is shown as “–.” The 5 polymorphic markers,
including the TBK1-(GT)n repeat polymorphism located 400 kb upstream of TBK1, are indicated at the left and flank the TBK1mutation p.Glu643del at both
sites. Genotypes of additional polymorphic markers can be found in table e-3. The 3 different disease haplotypes are shown with colored bars: green
haplotype of at least 7.5 Mb, purple haplotype of at least 8.7 Mb, and orange haplotype of at least 3.0 Mb. Haplotypes based on segregation data are
indicated in regular font, those based on allele sharing are in italics, and those that were inferred are between brackets. ALS5 amyotrophic lateral sclerosis;
FTD 5 frontotemporal dementia.
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all family members indicated that the disease
segregated with the p.Glu643del mutation on a
disease haplotype of minimal 7.5 Mb (figure 1).
Seven mutation carriers were without symptoms at
age $70 years, including obligate carrier II-5 and 2
children of II-5 who, at their last clinical evaluation,
were 79, 81, and 82 years of age, respectively (figure
1). Given the frequent occurrence of psychiatric
disease in family DR158, it cannot be excluded that
symptoms of FTD were not recognized (table e-2).
Carrier II-5 and one of her children with a current age of
81 years had repeated depression. Carrier II-3 died at
age 68 years and was diagnosed with schizophrenia.
One of the asymptomatic children of patient II-1 had
alcohol abuse and has a current age of 70 years. Among
the other 5 carriers of the p.Glu643del mutation and
their relatives, we identified 2 distinct disease haplotypes
that differed from that in DR158 (figure 1 and table
e-3). In family DR663, ALS patient II-1 and II-2
carried, besides the TBK1 mutation, a C9orf72 repeat
Table 1 Clinical characteristics of patients of family DR158 and TBK1 mutation carriers
Patient ID Sex AAO, y AAD, y DD, y Clinical diagnosis Family history Predicted proteina
Family DR158
II-1 F 71 81 10 D F p.Glu643del
II-2 F 86 90 4 D F p.Glu643del
III-1 M 69 72 3 ALS F p.Glu643del
III-2 M 69 75 6 FTD F p.Glu643del
III-3 M 70 73 3 D F p.Glu643del
III-4 M 63 — .3 FTD F NA
III-5 F 66 71 6 FTD F NA
III-6 F 61 74 13 FTD F p.Glu643del
III-7 F 63 69 6 D F p.Glu643del
III-8b F 62 74 11 FTD-ALS F p.Glu643del
III-9 F 73 84 11 D F p.Glu643del
III-10 F 82 86 4 D F NA
III-11 M 63 64 1 ALS F NA
Unrelated index patients
DR1120 F 56 60 4 FTD U p.Gln2*
DR1127 M 60 61 1 ALS S p.Asp167del
DR189 M 48 50 2 FTLDc F p.Gly272_Thr331del
DR1123 M 59 — .5 ALS U p.Ser398Profs*11
DR1124 F 64 64 ,1 ALSc U p.Ser518Leufs*32
DR158 F 62 74 11 FTD-ALS F p.Glu643del
DR467 F 64 — .9 FTD F p.Glu643del
DR1121 M 70 — .6 FTD F p.Glu643del
DR1122 F 69 — .7 FTD S p.Glu643del
DR1044 M 63 66 3 ALS S p.Glu643del
DR663 M 41 41 ,1 ALS F p.Glu643del
DR1132 M 80 87 7 FTD F p.Arg271Leu
DR609 M 52 62 10 FTD F p.Ala535Thr
DR1133 M 60 64 4 FTD F p.Lys291Glu
DR1134 M 64 66 2 ALS S p.His322Tyr
DR1135 F 59 — .10 ALS U p.Ile515Thr
Abbreviations: AAD 5 age at death; AAO 5 age at onset; ALS 5 amyotrophic lateral sclerosis; D5 dementia; DD 5 disease
duration; F 5 familial; FTD 5 frontotemporal dementia; FTLD 5 frontotemporal lobar degeneration; NA5 not analyzed; S 5
sporadic; U 5 unknown.
a Protein numbering according to NP_037386.1 isoform.
b Index patient of family DR158.
c TDP-43-positive pathology in brain or spinal cord.
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expansion, as did the asymptomatic sib II-4 without the
TBK1 mutation, age 63 years (figure 1).
Genotype–phenotype correlations. The mean onset age
in the 11 patients carrying a LOF mutation (table 1)
was 59.6 6 8.6 years. In 4 p.Glu643del carriers,
excluding the 2 patients carrying a C9orf72 repeat
expansion, we calculated a mean onset age of 66.3 6
3.9 years, which was significantly later (p 5 0.04)
than in the 5 patients with another LOF mutation,
with a mean onset age of 57.46 6.0 years. When we
included all affected carriers of family DR158, the
Figure 2 Transcript analysis of TBK1 loss-of-function mutations
Quantitative PCR quantification of TBK1 transcripts from lymphoblast cells (A) and frontal cortex (B) of LOF mutation
carriers (blue bars) compared to control persons without mutation (black bars) normalized to different housekeeping genes.
Five unrelated p.Glu643del mutation carriers were included. Error bars represent the SD. Below the chart is indicated if
cells were treated (1, dark blue bars) or not treated (2, light blue bars) with cycloheximide (CHX), a protein synthesis
inhibitor. Sequence traces are obtained by real-time PCR from the lymphoblast cells of the p.Ser398Profs*11 mutation
carrier treated or not treated with CHX using primers in exon 6 and exon 21. (C) Real-time PCR with primers in exon 6 and
10 of cDNA of brain of the p.Gly272_Thr331del mutation carriers is shown on agarose gel, with the respective sequence
traces from the aberrant transcripts.
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significance became stronger (p 5 0.004). Also, the
mean disease duration of 8.3 6 1.8 years was signif-
icantly longer (p 5 0.016) than the mean disease
duration of 2.6 6 2.2 years in the patients with
another LOF mutation with an increasing effect if
all DR158 patients were included (p 5 0.002). Four
of 5 FTD mutation carriers and the patient
with FTD-ALS had behavioral variant FTD
(bvFTD) (table e-2). The 3 patients with
FTD with a p.Glu643del mutation expressed
extrapyramidal symptoms, while the patients with
FTD with another TBK1 mutation did not
(table e-2). In 1 patient with bvFTD (DR1120),
muscular fasciculations were observed in 1 limb
(table e-2). The proband of DR158 presented with
spinal onset ALS; in the 3 other documented patients
with ALS (DR663, DR1123, DR1124), the site of
onset was bulbar (table e-2). Of 3 TBK1 mutation
carriers with ALS or FTD-ALS (DR158.III-8,
DR1123, DR1124), we had EMG reports, while of
3 other patients with ALS (DR663, DR1044,
DR1127), no detailed information was available.
Based on a clinical examination, there was no
cognitive evidence for FTD in the majority of ALS
cases. However, in ALS patient DR1124 memory
deficits and the impression of behavioral
disinhibition were reported (table e-2), but we did
not have sufficient information to determine if the
criteria for possible FTLD were fulfilled.
Neuropathologic brain examination of FTD
patient DR189 (p.Gly272_Thr331del) showed mild
neuronal loss of the frontal cortices. We found a mod-
erate amount of TDP-43 and p62 neuronal cytoplas-
mic inclusions (NCI) and short dystrophic neurites
Figure 3 Protein analysis of TBK1 loss-of-function mutations
Western blot analysis of protein extracts from lymphoblast cells (A) and frontal cortex (B) of loss-of-function (LOF) mutation
carriers compared to control persons without mutation. Of the p.Glu643del mutation, 5 unrelated index patients were
included. The upper band represents TBK1 (84 kDa) and the lower band the housekeeping protein GAPDH (37 kDa). The
graphs below (C) show the quantification in control samples (black) and patient samples (blue) of the TBK1 signal normalized
to the signal of GAPDH. Error bars represent the SD; ** indicates a significant p value of ,0.01 compared to controls.
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but no intraneuronal intranuclear inclusions (figure
4, A, B, D, and E) compatible with a TDP type B
proteinopathy.13 In ALS patient DR1124
(p.Ser518Leufs*32), pathologic signs of lower and
upper motor neuron disease were apparent. The
TDP-43 positive NCI were mainly restricted to the
hypoglossal nucleus and the ventral horn neurons of
cervical and thoraco-lumbar spinal cord (figure 4,
C, F). Staining with TBK1 showed variable cytoplas-
mic neuronal immunoreactivity. The Nissl substance
of the neurons in the ventral horn of the spinal cord
was stained. We did not observe differences between
patients and controls (figure 4, G–L).
DISCUSSION The overall TBK1 LOF mutation fre-
quency is 1.7% (11/629), with 1.1% (5/460) in
FTD, 4.5% (1/22) in FTD-ALS, and 3.4% (5/147)
in ALS. In patients with FTD, TBK1 LOF mutations
explained 3.2% of the unexplained familial FTD
cases and were the third most common genetic
cause after C9orf72 and GRN mutations (figure
e-3), consistent with the findings in a FTLD-TDP
Figure 4 TDP-43, p62, and TBK1 immunohistochemistry
Immunohistochemistry of frontal cortex (A, D, G) and hippocampus (B, E, H) of 1 patient with frontotemporal lobar degeneration with the p.Gly272_Thr331del
mutation (DR189) and spinal cord (C, F, I) of 1 patient with amyotrophic lateral sclerosis (ALS) with the p.Ser518Leufs*32 mutation (DR1124) compared to a
control individual without mutation (J–L). In frontotemporal dementia patient DR189, a mild neuronal loss of the frontal cortices and to a lesser extent of the
temporal neocortex and the hippocampus was shown. A moderate amount of TDP-43 and p62 neuronal cytoplasmic inclusions (NCI) (arrows) and short dys-
trophic neurites, but no intraneuronal intranuclear inclusions, were found throughout all layers of the frontal (A, D) and temporal neocortices, in the dentate gyrus
of the hippocampus (B, E), the parahippocampal transentorhinal cortex, the neostriatum, and the pallidum, but not in the cerebellum. In ALS patient DR1124, no
explicit cortical abnormalitieswere present, but pathologic signs of lower and uppermotor neuron diseasewere apparent. Severe demyelination of the pyramidal
tract inmesencephalon, pons, medulla oblongata, and the entire spinal cord and severe neuronal loss in the hypoglossal nucleus, as well as in the ventral horns of
the cervical and thoracic spinal cord, were observed. The TDP-43-positive (C) and p62-positive (F) NCI weremainly restricted to the hypoglossal nucleus and the
ventral horn neurons of cervical and thoraco-lumbar spinal cord (arrows). Cytoplasmic TBK1 immunoreactivity (arrows) in cortical neurons of the frontal cortex
(G, J), in the dentate gyrus of the hippocampus (H, K), and in the cervical ventral horn neurons (I, L) showed nodifferences betweenpatients and controls. The TDP-
43-positive inclusions were not stained with TBK1.
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cohort.8 In the ALS cohort, TBK1mutations were the
second most common after C9orf72 mutations
(figure e-3).
All described LOF mutations, except 1, are
different from those in the other published reports.
The p.Glu643del mutation that was present in 6/
629 (1%) unrelated Belgian patients was also found
in 2/1,010 German patients with sporadic ALS.7
We showed segregation of the p.Glu643del mutation
with disease. The presence of 3 different disease hap-
lotypes of at least 3 Mb among the p.Glu643del car-
riers might be explained by a mutation hotspot due to
a repetitive (GAA)3 sequence encoding 3 Glu residues
(codons 641–643) or because of an extreme distant
common founder. Expression studies in lymphoblast
cells and in brain of 3 LOF mutation carriers con-
firmed the loss of transcript and of protein leading to
50% reduced protein levels, as previously reported.7,8
A novel finding is that the p.Glu643del mutation had
no effect on transcript levels but resulted in a near
50% reduced protein expression in blood, possibly
due to loss of protein stability. The p.Asp167del
mutation and the missense mutations did not show
reduced transcript or protein levels, but we cannot
exclude their pathogenicity by mechanisms like
reduced kinase activity or hampered protein dimer-
ization. TBK1 has a 4-domain structure with an
N-terminal kinase domain (KD), a ubiquitin-like
domain, an a-helical scaffold dimerization domain,
and a C-terminal domain14 (figure e-1). The correct
interplay among these domains is essential for proper
kinase function. TBK1 is activated by trans-
autophosphorylation of serine 172 (Ser172), for
which homodimerization is required.15,16 Ser172 is
located in a kinase activation loop of the KD starting
at the conserved DFG motif (residues 157–159)
and extending to residue 198.15 Interestingly, the
p.Asp167del mutation is located in this activation
loop and hence might hamper the conversion of
TBK1 to the active state. In other TBK1 reports,
some missense mutations were found to be patho-
genic.7,8 Since at least one of the used prediction
algorithms predicted that some of our missense mu-
tations are pathogenic, we expect that some might
hamper proper protein functioning. Further experi-
ments are necessary to confirm these predictions.
Clinical heterogeneity among the TBK1 mutation
carriers was apparent since all different phenotypes of
the FTD-ALS spectrum and a wide range in age at
onset and disease duration were present, comparable
to what was observed in C9orf72 expansion carriers.17
However, remarkably, 5 of 6 FTD or FTD-ALS
index patients with a TBK1 mutation presented with
bvFTD. The later onset age and longer disease dura-
tion associated with the p.Glu643del mutation sug-
gested that this mutation has a milder pathogenic
effect. Since amnestic deficits and orientation prob-
lems were apparent early in the disease process, it
might be interesting to screen TBK1 in patients with
clinically diagnosed AD, also since in another study 2
of 4 patients with FTLD-TDP with a TBK1 muta-
tion presented with clinical AD.8 In ALS family
DR663, we found both the TBK1 p.Glu643del
mutation and a C9orf72 repeat expansion (.80
repeat units) segregating with disease. The 2 sibs
who carried both mutations had a remarkably
younger onset age (41 and 51 years) and a shorter
disease duration (,1 and 2 years) compared to the
other p.Glu643del mutation carriers. Also, one other
index patient of the ALS cohort, DR1044, carried
both the TBK1 p.Glu643del mutation and a
C9orf72 repeat expansion of only 59 repeat units.
This patient had later onset age of 63 years, corrob-
orating our recent findings that patients with a short
repeat expansion (45–80 units) have a later age at
onset compared to patients with a longer expansion.18
Further, the disease penetrance in p.Glu643del muta-
tion is highly variable, with 7 carriers of family
DR158 still unaffected at age $70 years, with 2 at
age 81 and 82 years, nearly 2 SDs beyond the mean
onset age. The 7 unaffected carriers were not homo-
zygous for the minor protective allele of TMEM106B
rs1990622.19 The observed TDP-43 type B pathol-
ogy in brain or spinal cord could be distinguished
from that in patients with a C9orf72 mutation by
the absence of p62-positive inclusions containing
dipeptide repeats.20,21 This pathology was previously
reported in 1 patient with FTD-ALS7 while another
study reported FTLD-TDP type A in 3 mutation
carriers.8
The observation that TBK1 mutations were pre-
sent in a significant part of sporadic and late-onset
patients is not uncommon in adult-onset neurodegen-
erative diseases because of reduced penetrance, similar
to what is described for C9orf72 mutations and to a
lesser extent for GRN mutations.9 A relatively high de
novo mutation rate may be another explanation,
supported by the observation that the p.Glu643del
mutation occurred on 3 different haplotype back-
grounds. Also, as proposed by others,8 more than
1 gene might be involved in some patients, as observed
in family DR663 segregating both a TBK1 and a
C9orf72 mutation.
TBK1 is an important serine/threonine kinase of
the IKK family phosphorylating a wide range of sub-
strates involved in several cellular processes, including
innate immune response/inflammation,22 autoph-
agy,23,24 and cell proliferation.25 Substrates of TBK1
include optineurin (OPTN),26,27 another gene with
LOF mutations in ALS,28 and p62, a major compo-
nent of pathologic depositions and showing muta-
tions in FTLD and ALS.29,30 p62 and OPTN are 2
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autophagic adapters controlling protein degradation
by selective autophagy.31,32 Moreover, TBK1 targets
the VPS37C protein of the endosomal sorting com-
plex required for transport-I,33 thereby regulating the
vesicular retroviral budding system, which is also
involved in neurodegeneration, e.g., CHMP2B.34 A
dysfunctional vesicular transport system might in
turn induce autophagy defects.35 As other FTD/
ALS genes, including VCP,36 are also involved in
autophagy, and since mutations in OPTN and
TBK1 are also involved in glaucoma,37,38 our findings
emphasize the major role of autophagic defects in
neurodegeneration.39 Also, in the antiviral innate
immune response both TBK1 and OPTN are
involved through the NF-KB complex pathway.40
In this study, we demonstrated that LOF muta-
tions in TBK1 are associated with FTD-ALS spec-
trum disorders in a Belgian clinical patient cohort,
can segregate in families according to an autosomal
dominant pattern, and are present in a significant part
of sporadic cases. The identification of TBK1 empha-
sizes the convergence of FTD and ALS in 1 contin-
uum and will accelerate effective drug development.
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